Medigene AG Gains Two More Patents for Its Platform Technologies

Medigene AG, an oncology platform company based in Planegg/Martinsried and known for its advanced research in T cell receptor (TCR)-guided therapies, recently announced the issuance of two significant patents. The European Patent Office has granted the company a patent for its JOVI technology, while the Hong Kong Patent Office has issued a patent for its inducible Medigene T cell receptor (iM-TCR) technology. These additions strengthen Medigene’s intellectual property portfolio and enhance its therapeutic capabilities in cancer treatment.

The JOVI technology uses a specific anti-Cβ antibody to enrich T cells, enabling a high-throughput comparison approach. This method facilitates the selection of optimal TCRs based on their efficacy and safety profiles, which is crucial for developing superior TCR-T therapies. The technology not only enhances TCR-T therapies but also has potential applications in other TCR-guided modalities, including TCR-T cell engagers and TCR-natural killer cell therapies.

The iM-TCR technology addresses the challenge of overactivation in TCR-T therapies. T cells engineered with this technology can have their activity finely tuned, allowing for controlled modulation of their presence on the cell surface. This capability minimizes the risk of inflammatory side effects and improves the safety and efficacy of TCR-T therapies. The technology can also be applied to other TCR-guided approaches, making it a versatile tool in cancer immunotherapy.

Dolores Schendel, Chief Scientific Officer at Medigene, highlighted the importance of these patents in establishing a robust international intellectual property portfolio. According to Schendel, the proprietary JOVI and iM-TCR technologies underscore the company’s commitment to advancing TCR-guided therapies for cancer treatment. She emphasized Medigene’s expertise in generating optimal TCRs, which are specific, sensitive, and safe, and can be utilized across various therapeutic modalities.

Medigene’s End-to-End (E2E) Platform plays a crucial role in the development of TCR-guided therapies. The platform is built on proprietary technologies that enable the generation and optimization of highly specific TCRs. It incorporates advanced features like Allogeneic-HLA TCR Priming and integrates product armoring and enhancement techniques, such as PD1-41BB and CD40L-CD28 costimulatory switch proteins. These features ensure the development of cell therapy drug products with improved safety, efficacy, and durability.

Medigene’s lead TCR-T program, MDG1015, is designed to treat multiple solid tumor indications and is considered a potential best-in-class therapy. The E2E Platform enables the armoring and enhancement of T cells to overcome the immunosuppressive tumor microenvironment, maximizing the safety and efficacy of the T cell drug product composition. The program is on track for an Investigational New Drug (IND) filing in the third quarter of 2024 and a Clinical Trial Application (CTA) filing in the fourth quarter of 2024.

In addition to its in-house product pipeline, Medigene collaborates with partners like BioNTech, Regeneron, and WuXi Biologics. These partnerships further leverage the capabilities of the E2E Platform and underscore its potential to revolutionize cancer treatment.

Medigene AG remains at the forefront of immuno-oncology, driven by its innovative approaches and proprietary technologies. The recent patents for JOVI and iM-TCR technologies represent significant milestones in the company’s mission to develop effective and safe TCR-guided therapies for cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!